



BRITISH GENERIC MANUFACTURERS ASSOCIATION

**Wednesday, November 6<sup>th</sup>, 2013**

## **Reaction to the agreement on the outline terms of the 2014 Pharmaceutical Price Regulation Scheme (2014 PPRS).**

Warwick Smith, Director General of the British Generic Manufacturers Association (BGMA), which represents 90% of generic manufacturers in the UK, said: "The UK medicines industry is extremely efficient, providing patients with a stable supply of affordable and accessible medicines throughout their life cycle. The British Generic Manufacturers Association (BGMA) welcomes any policies which increase access to innovative and proven medicines for patients.

"The mature competitive generic market in the UK already saves the NHS £11billion a year and provides important headroom to allow further investment into the uptake of new medicines."

[www.britishgenerics.co.uk](http://www.britishgenerics.co.uk)

ENDS

For further information contact:

Jeremy Durrant, 020 7866 7883 / 07792 918648

[Jeremy.durrant@britishgenerics.co.uk](mailto:Jeremy.durrant@britishgenerics.co.uk)

### Notes for Editors:

The British Generic Manufacturers Association represents the interests of UK-based manufacturers and suppliers of generic medicines and promotes the development and understanding of the generic medicines industry in the United Kingdom.

Generic medicines contain the same active ingredient and are as effective as the equivalent brand and cost much less, making the NHS drugs bill affordable. More than two thirds of all medicines dispensed by the NHS are generics yet they cost only around 29% of the NHS drugs bill, a saving of more than £11billion\* in England & Wales alone. Without generics, the NHS drugs bill would be approximately twice its current level.

We represent the views and interests of our members and industry to the UK government, the devolved administrations, regulators, other relevant third parties, including where appropriate the Institutions of the European Union.